Toronto – October 14, 2026 -- Real-world discontinuation of weight-loss medications can reach 67% within 12 months, while clinical trials show sustained weight reduction of 15–22% over 72 weeks, according to materials for an Xtalks webinar featuring Clinical ink executives on October 29.
Psychology, not only side effects, drives discontinuation of obesity therapy
Side effects, cost and access explain only part of the drop-off, the organizers state. Confidence, doubt and treatment identity are increasingly recognized as independent predictors of discontinuation. Motivations differ by patient, rooted in appearance, day-to-day function or long-term health risk.
Most patient support programs have no validated way to identify behavioral risk before it affects outcomes, creating a gap for pharma teams managing obesity portfolios.
Clinical ink presents a 1,056-patient US study on GLP-1/GIP users
The speakers will discuss findings from a study of 1,056 US adults using a GLP-1/GIP medication for weight management. The study applied the SPUR behavioral framework alongside validated belief and mental-health measures.
Clinical ink will also introduce KaitalityTM, its general wellness app. The session will show how three data streams can generate real-world evidence and support earlier outreach to at-risk patients:
- Biometrics: weight, body composition and activity
- Sociometrics: social context and daily environment
- Psychometrics: validated psychological drivers of adherence
Three Clinical ink executives lead the October 29 session
Christian Djurhuus, MD, PhD, EVP Disease Management and Chief Scientific Officer, and Nicholas Alp, MD, PhD, FACC, Chief Medical Officer, will speak. Bob DiLuzio, Senior Vice President, Disease Management, will moderate.
The live webinar runs Thursday, October 29, 2026, at 11am EDT (4pm CET).